RM
RMD.AU Resmed Inc
- Market cap
- AUD 49.9B
- P/E
- 22.3x
- P/B
- 5.92x
- ROE
- 28.3%
- Dividend yield
- 10.54%
- Fundamental score
- 3.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is RMD.AU undervalued?
Graham numberRMD.AU trades 142.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Resmed Inc fundamental analysis
16 of 22 checks passedROE 2/2
High return on equity (28.3%), above 20%.
ROA 1/1
Return on assets (20.5%) is above the industry median (-35.3%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (12.1%) is not above the 5-year average (26.9% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (12.1%) is below the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 11.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (10.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (22.3x) is above the market median (15.0x).
PE vs Industry 1/1
PE (22.3x) is below the industry median (36.4x).
PBV 0/1
Price to book (5.9x) is above the industry median (4.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 132.3, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.83, growth is cheap.
Dividend Yield 0/2
Dividend yield (1.0%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 23.0%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Resmed Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Resmed Inc
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl…
Full company profileResmed Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Resmed Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.07B | 2.34B | 2.61B | 2.96B | 3.20B | 3.58B | 4.22B | 4.69B | 5.15B | 5.78B | 5.68B |
| Gross Profit | 1.20B | 1.36B | 1.54B | 1.72B | 1.84B | 2.02B | 2.36B | 2.66B | 3.05B | 3.48B | 3.46B |
| Operating Income | 426M | 542M | 579M | 810M | 912M | 1.00B | 1.15B | 1.38B | 1.69B | 1.96B | 1.82B |
| EBITDA | 569M | 680M | 706M | 990M | 1.10B | 1.18B | 1.35B | 1.53B | 1.92B | 2.21B | 2.03B |
| Net Income | 342M | 316M | 405M | 622M | 475M | 779M | 898M | 1.02B | 1.40B | 1.56B | 1.68B |
| EPS | 0.24 | 0.22 | 0.28 | 0.43 | 0.32 | 0.53 | 0.61 | 0.69 | 0.95 | 1.07 | 1.17 |
| Balance Sheet | |||||||||||
| Total Assets | 3.47B | 3.06B | 4.11B | 4.11B | 4.73B | 5.10B | 6.75B | 6.87B | 8.17B | 8.96B | 8.19B |
| Total Liabilities | 1.51B | 1.00B | 2.04B | 2.04B | 1.84B | 1.74B | 2.62B | 2.01B | 2.21B | 2.38B | 2.26B |
| Shareholders' Equity | 1.96B | 2.06B | 2.07B | 2.07B | 2.89B | 3.36B | 4.13B | 4.86B | 5.97B | 6.58B | 5.93B |
| Cash & Short-term Investments | 822M | 189M | 147M | 147M | 295M | 274M | 228M | 238M | 1.21B | 1.47B | 1.01B |
| Total Debt | 1.29B | 281M | 1.27B | 1.27B | 794M | 918M | 1.58B | 899M | 852M | 826M | 609M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 414M | 505M | 459M | 459M | 737M | 351M | 693M | 1.40B | 1.75B | 1.85B | 1.70B |
| Capital Expenditure | 71.5M | 71.5M | 77.3M | 77.3M | 117M | 156M | 134M | 115M | 101M | 160M | 196M |
| Free Cash Flow | 343M | 434M | 382M | 382M | 620M | 195M | 559M | 1.29B | 1.65B | 1.69B | 1.50B |
| Ratios | |||||||||||
| ROE | 17.5% | 15.3% | 19.5% | 30.0% | 16.4% | 23.2% | 21.7% | 21.0% | 23.5% | 23.6% | 28.3% |
| ROA | 9.9% | 10.3% | 9.8% | 15.1% | 10.0% | 15.3% | 13.3% | 14.9% | 17.1% | 17.4% | 20.5% |
| Net Profit Margin | 16.6% | 13.5% | 15.5% | 21.0% | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% | 29.6% |
| Debt to Equity | 0.66x | 0.14x | 0.61x | 0.61x | 0.28x | 0.27x | 0.38x | 0.18x | 0.14x | 0.13x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Resmed Inc dividends
- Dividend yield
- 10.54%
- Forward dividend
- 3.74 AUD
- Payout ratio
- 23.0%
- Ex-dividend date
- Nov 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 357M | 0.24 | 23.0% |
| 2025 | USD 311M | 0.21 | 22.2% |
| 2024 | USD 282M | 0.19 | 27.7% |
| 2023 | USD 258M | 0.18 | 28.8% |
| 2022 | USD 245M | 0.17 | 31.5% |
| 2021 | USD 227M | 0.15 | 47.8% |
| 2020 | USD 225M | 0.16 | 36.2% |
| 2019 | USD 212M | 0.15 | 52.3% |
| 2018 | USD 199M | 0.14 | 63.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 12, 2010.
Who owns Resmed Inc
- Insiders 0.00%
- Institutions 9.77%
- Public & others 90.23%
- Shares outstanding 1.41B
- Free float 569M
Resmed Inc company profile
- Company name
- Resmed Inc
- Ticker
- RMD.AU
- ISIN
- AU000000RMD6
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 11,370
- Fiscal year end
- June
- Address
- 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
- Phone
- 858-836-5000
- Website
- resmed.com
About Resmed Inc
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Resmed Inc management
10- Mr. Michael J. Farrell BE, MBA, SMCEO & Chairman · born 1972
- Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScDFounder, Chair Emeritus & Non-Executive Director · born 1942
- Mr. Aaron BloomerChief Financial Officer · born 1986
- Mr. Michael J. RiderChief Legal Officer & Secretary · born 1958
- Mr. Brett A. SandercockAdvisor · born 1967
- Mr. Justin LeongChief Product Officer · born 1977
- Mr. Alastair RobertsonChief Information Officer
- Ms. Sallilyn SchwartzChief Communications & Investor Relations Officer
- Mr. Jim EllisChief Compliance Officer
- Ms. Yvonne-Katrin PucknatChief Marketing Officer · born 1976